iShares US Pharmaceuticals ETF
76 hedge funds and large institutions have $202M invested in iShares US Pharmaceuticals ETF in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
29% more capital invested
Capital invested by funds: $157M → $202M (+$45.3M)
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
21% more funds holding
Funds holding: 63 → 76 (+13)
11.86% more ownership
Funds ownership: 95.09% → 106.95% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$4.62M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.99M |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
+$2.61M |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$1.82M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$2.82M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$2.32M |
| 3 |
Morgan Stanley
New York
|
-$877K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$665K |
| 5 |
SG Americas Securities
New York
|
-$637K |
IHE Hedge Fund Activity: Q4 2013 in Review
76 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2013, worth a combined $202M — up 29% from $157M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IHE positions and 3 closed out — a net gain of 15 holders — while 23 added to existing stakes and 18 trimmed.
The largest buyer was Clark Capital Management Group, opening a new position worth an estimated $4.62M. The largest seller was Brinker Capital Investments, cutting an estimated $2.82M.
- 76 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2013, up from 63 in Q3 2013.
- Funds reported $202M of iShares US Pharmaceuticals ETF stock for Q4 2013, up 29% quarter-over-quarter.
- 18 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2013 and 3 closed out, a net change of +15 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2013 was Clark Capital Management Group, an estimated $4.62M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2013 was Brinker Capital Investments, an estimated $2.82M sold.
Based on aggregated 13F filings for Q4 2013.